Agalsidase alfa

Drug Profile

Agalsidase alfa

Alternative Names: Replagal; SMP 536; α-galactosidase A

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Shire
  • Developer Endo International; Medison Pharma; Orphan Australia; Samaritan Pharmaceuticals; Shire; Sumitomo Dainippon Pharma
  • Class Galactosidases; Isoenzymes
  • Mechanism of Action Alpha-galactosidase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fabry's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Fabry's disease

Most Recent Events

  • 19 Jun 2014 Dainippon Sumitomo Pharma is now called Sumitomo Dainippon Pharma
  • 28 Feb 2014 Endo Health Solutions and Paladin Labs combine to form Endo International
  • 29 Mar 2012 Efficacy and adverse events data from an expanded access trial in Fabry's disease presented at the 2012 ACMG Annual Clinical Genetics Meeting (ACMG-2012)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top